Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponsegromab in advanced cancer with anorexia
NCT04803305Phase 1Completed
- Sponsor
- Pfizer
- Start
- May 2021
- Primary completion
- Apr 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of ponsegromab in cancer cachexia and anorexia nervosa (AN), sponsored by Pfizer. Primary endpoint: Change From Baseline in Cancer-Related Cachexia Symptom Assessment in Appetite Score at 4 weeks. Started May 2021; status: completed.
02
Drugs
ponsegromab
03
Conditions
cancer cachexiaanorexia nervosa (AN)
Beyond the preview
Go deeper on NCT04803305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04803305.